PDF(Pubmed)
Abstract：
Behcet\'s disease (BD) is a multisystem disease with altered Toll-like receptors (TLRs) on macrophages. Long noncoding RNA Maternally expressed gene 3 (lncRNA MEG3) and lncRNA Musculoaponeurotic fibrosarcoma oncogene family, protein G antisense 1 (MAFG-AS1) are regulators of microRNA (miRNA) 147-b, which is induced upon TLR stimulation. We included fifty BD patients, and fifty age and sex-matched controls. Real-time polymerase chain reaction (PCR) was used to measure the expression levels of serum lncRNA MEG3, lncRNA MAFG-AS1, and miRNA 147-b. LncRNA MEG3 and lncRNA MAFG-AS1 were significantly downregulated while miRNA 147-b was significantly upregulated in the BD patients\' serum compared to the controls with p-value <0.001. Receiver operation characteristics (ROC) curve analysis revealed that the three biomarkers can discriminate between BD and control subjects with 76%, 100%, and 70% sensitivity respectively, and 100% specificity for all of them. There was a lower expression level of lnc RNA MEG3 among patients who had new eye involvement in the last month in comparison to those without new eye involvement (p-value=0.017). So, LncRNA MEG3, lncRNA MAFG-AS1, and miRNA147-b are promising diagnostic markers and therapeutic targets for BD patients. LncRNA MEG3 can be used as a predictor for new BD ocular involvement.
摘要：
Behcet病(BD)是巨噬细胞Toll样受体(TLRs)改变的多系统疾病。长链非编码RNA母体表达基因3(lncRNAMEG3)和lncRNA肌膜膜纤维肉瘤癌基因家族,蛋白G反义1（MAFG-AS1）是microRNA（miRNA）147-b的调节因子，这是在TLR刺激下诱导的。我们纳入了50名BD患者，和50个年龄和性别匹配的对照。实时聚合酶链反应（PCR）用于测量血清lncRNAMEG3，lncRNAMAFG-AS1和miRNA147-b的表达水平。与p值<0.001的对照相比，BD患者血清中的LncRNAMEG3和lncRNAMAFG-AS1显着下调，而miRNA147-b显着上调。受试者操作特征（ROC）曲线分析显示，这三种生物标志物可以区分BD和对照受试者，占76％，100%,灵敏度分别为70%,对所有这些都有100%的特异性。与没有新的眼睛受累的患者相比，在上个月有新的眼睛受累的患者中lncRNAMEG3的表达水平较低（p值=0.017）。所以,LncRNAMEG3，lncRNAMAFG-AS1和miRNA147-b是BD患者的有希望的诊断标记和治疗靶标。LncRNAMEG3可作为新的BD眼部受累的预测因子。
